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Received November 28, 2011; accepted February 7, 2012AbstractBackground: Acute gastrointestinal bleeding (GIB) is a life-threatening abdominal emergency and can be treated by transarterial embolization
(TAE). Rehemorrhage and poor outcome are associated with several clinical factors. This study investigated the clinical and angiographic
parameters associated with treatment failure for patients with acute GIB undergoing TAE.
Methods: Sixty-seven patients who had angiographic evidence of contrast extravasation and who received subsequent TAE were included in this
study. Treatment failure was defined as continuous or recurrent bleeding that required surgery within 7 days after the bleeding episode and/or
death within 1 month. Univariate and multivariate logistic regression was applied to analyze the clinical and angiographic parameters affecting
treatment failure.
Results: Patients were divided into two groups: success (n ¼ 35, 52.3%) and failure (n ¼ 32, 47.7%). In the failure group, 22 patients (68.9%)
re-bled and then received surgery. With the aid of angiographic localization, 68.2% (15 of 22 patients) survived after surgery. The other 10
patients who did not receive surgery died within 30 days. Several clinical and angiographic parameters analyzed by multivariate analysis were
associated with treatment failure ( p < 0.05), including presence of coagulopathy [odds ratio (OR), 14.7], number of supplying arteries >1 (OR,
13.2), and a distance of >5 cm (OR, 6.3) during TAE.
Conclusion: Angiographic parameters associated with treatment failure in patients undergoing TAE are established when the number of
supplying arteries is >1, and a distance of >5 cm. Patients with these risk factors should be watched carefully for recurrence in the post-
procedural period.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Acute nonvariceal gastrointestinal bleeding (GIB) is a life-
threatening abdominal emergency, as an admission diagnosis
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http://dx.doi.org/10.1016/j.jcma.2012.06.005mortality rates of approximately 4e10%.1,2 In the over-
whelming majority of patients with acute GIB, the bleeding
either resolves spontaneously or can be controlled endoscop-
ically. Despite conservative medical treatment or endoscopic
intervention, however, severe bleeding occurs in 5e10% of
patients who require surgery or angiographic intervention,
either to locate or to control the source of bleeding.3,4
The outcome of surgery in acute GIB largely depends upon
the identification of the bleeding site, the general condition of
the patient, and the type of operation.5 A preoperative site-hinese Medical Association. All rights reserved.
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mine whether a localized, minimally invasive procedure or
a large, blind resection should be performed. This, in turn, has
a profound influence on morbidity and mortality.6 In patients
with an unclear bleeding source or with poor risk status for
surgical intervention, visceral arteriography has been advo-
cated to identify bleeding sources, and, at the same time, to
provide control of the GIB by embolization of particulate
matter into the bleeding artery.7 Surgery is typically reserved
for those patients whose bleeding fails to respond to endo-
scopic and angiographic treatments.
With recent advances in endovascular technology, trans-
arterial embolization (TAE) for GIB has gained much atten-
tion. An increasing number of patients with GIB are being
referred to the endovascular suite after failed endoscopic
management.8,9 Since 1972, TAE has been performed exten-
sively, and has been shown to be effective at controlling
hemorrhage and decreasing mortality.9e12 Nevertheless, in
spite of advances in technology and methods, which have
allowed more patients to be successfully treated via TAE,
angiographic control of GIB still fails in a number of patients,
necessitating surgical intervention.
Several clinical risk factors are associated with
rehemorrhage and poor outcome, such as presence of
coagulopathy,11,13e15 presence of multiple comorbidities13,14
or use of coils as the only embolic agent.14,15 However,
angiographic factors predicting treatment failure have not been
addressed. The purpose of the present retrospective study was
to analyze the association of demographic, clinical, and
angiographic characteristics with treatment failure.
2. Methods2.1. Patient identificationThis study was conducted retrospectively at a tertiary
referral medical center between January 2006 and March
2011. A search of the institutional database for interventional
radiology identified 107 consecutive patients who underwent
diagnostic angiography for GIB. Angiographic evidence of
bleeding was detected in 67 patients. TAE was subsequently
performed in these 67 patients, who were included in this
study. There were 44 men and 23 women, with a mean age of
67.7 years (range ¼ 21e94 years). All 67 patients had been
referred by gastroenterologists and were considered on clinical
grounds to be actively bleeding at the time of angiography. All
patients had failed to respond to conservative medical therapy
consisting of volume replacement, antacids, or H2 receptor
blocking agents (in patients with upper gastrointestinal
bleeding), and all patients experienced continued bleeding
despite attempted endoscopic treatment.
The study was approved by the institutional review board
for human investigation (TSGHIRB-099-05-221). Written
informed consent was waived because of strict maintenance of
patient anonymity and the observational nature of the study.
This study complies with the standards of Declaration of
Helsinki and current ethical guidelines.2.2. Methods and techniques for transarterial
embolizationInformed consent for the procedure was obtained from the
conscious patient or the immediate family. The right common
femoral artery was accessed, and selective arteriography of the
celiac trunk and superior mesenteric artery was performed
with a 4.1-F catheter (RC-1, Cook, Bloomington, IN, USA)
and a non-ionic contrast medium (Ultravist, Schering AG,
Berlin, Germany) was injected at a flow rate of 3e3.5 mL/
second. Inferior mesenteric arteriography required a lower
injection rate of 2e2.5 mL/second. Images were obtained with
the digital subtraction technique. When GIB was confirmed
and localized unequivocally by a demonstration of contrast
extravasation at angiography, superselective embolization was
performed, with a 2.7-F hydrophilic angiographic catheter
(Radiofocus Guide Wire M, Terumo, Tokyo, Japan) coaxially
inserted into a 4.1-F catheter.
The principle for TAE is similar with other studies.9,15,16
For embolotherapy, we delivered vascular platinum micro-
coilsof various diameters and lengths close to the site of
contrast medium extravasation and in areas proximal and
distal to the bleeding site via superselective catheterization. If
the guide wire could not be extended into the distal portion of
the bleeding site, the portion distal to the bleeding point was
embolized by using gelatin sponge pieces (Spongostan,
Johnson & Johnson Medical, Midrand, South Africa), fol-
lowed by embolization of the proximal portion with micro-
coils. If direct entry into the bleeding artery was not possible,
it was treated by means of flow-directed injection of gelatin
sponge pieces. When a combination of agents was used,
gelatin sponge was injected into the desired territory until
stagnation was observed, and coils were then placed inside the
target vessel to complete the occlusion. Finally, a post-
embolization arteriography was performed to confirm the
absence of contrast extravasation. The choice of embolic agent
and the final number and selection of embolized arteries in the
procedure was case dependent and was ultimately left to the
discretion of the radiologists who had 21 years (C.Y.Y.), 10
years (C.H.L.), and 7 years (W.C.C.) of experience in inter-
ventional radiology, respectively.
The patients then received supportive medical therapy in
the intensive care unit. They were observed in particular for
ischemic complications. Patients with subsequent bleeding
were referred for surgery or endoscopy, but not for repeat
arteriography.2.3. Clinical dataAll clinical, laboratory, and medication information, as well
as the treatment given and outcome data, were obtained from
the medical records. Acute GIB was defined as hematemesis,
melena, or bloody stool within 24 hours prior to embolization.
Blood loss was quantified by measuring the hemoglobin
concentration and the amount of blood products transfused
0e2 days prior to embolization. The numbers of transfused
units of packed cells, fresh frozen plasma and platelets before
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the following criteria were identified as having coagulopathy:
international normalized ratio (INR) > 1.6, partial thrombo-
plastin time > 45 seconds, or thrombocytopenia with a platelet
count < 50,000 per cubic millimeter (5  1010 per L).
Clinical success was defined as clinical cessation of
bleeding (clearing of nasogastric aspirates and/or melena with
no evidence of bleeding on follow-up endoscopy) and stabi-
lization of the hemoglobin level after the procedure. If
a patient had continuous or recurrent active bleeding which
required surgery within 7 days after the angiographic proce-
dure, and/or death occurred within 1 month after the primary
procedure, the procedure was termed a failure. Repeat
embolizations were excluded from the analysis, regardless of
the outcome.
From the medical records, the following variables were
recorded: demographic data, clinical diagnoses, major
comorbidities, medications, hemoglobin concentration before
and after embolization, total transfusion requirements, pres-
ence of shock, coagulation profiles, post-procedure compli-
cations, and mortality rates.2.4. Angiographic image reviewThe names and identifying patient record numbers were
electronically removed from all images for each angiographic
examination prior to loading of the cases onto a workstation
for review. The age and sex of the patient and the date of the
angiography were not removed. Two gastrointestinal radiolo-
gists (W.C.C. and C.Y.Y., with 7 and 21 years of experience in
abdominal imaging and interventional radiology, respec-
tively), who were blinded to patient identification and surgical/
angiographic diagnosis, independently reviewed each angio-
graphic study and recorded the angiographic findings.
The angiographic findings were individually recorded as
follows: (1) anatomic location of contrast extravasation; (2)
bleeding vascular territory; (3) number of arteries supplying
the bleeding point; (4) the shortest intra-arterial distance
between the catheter tip at time of embolization and the
bleeder and (5) presence of pseudoaneurysm. Discrepancies
between the two reviewers were resolved by further consensus
readings, and these consensus readings were also used for
analysis.2.5. Short-term follow-upThe final etiology of GIB was traced by consensus analysis
(W.C.C. and C.Y.Y.) incorporating the history and all imaging
findings and histological and autopsy findings, if available.
The follow-up medical records were reviewed to determine
whether the patients experienced ongoing blood loss and
whether subsequent surgery or repeat angiographic procedures
were required. After completion of angiographic intervention,
a rebleeding episode was defined as a subsequent bleeding
episode that occurred after the initial bleed had stopped within
72 hours. The 30 day mortality rates were recorded. We also
checked whether the patient had further blood transfusions toreplace ongoing blood loss, whether the patient required
further intervention in the form of a repeat embolization or
surgery to stop bleeding and whether the patient died because
of acute hemorrhage or hemorrhage-related complications.2.6. Statistical methodsStatistical analyses were performed using SPSS version
14.0 software (SPSS Inc., Chicago, IL, USA). Descriptive
statistics were reported as mean and standard deviation (SD)
or median and range for continuous variables. Categorical
variables were expressed as frequencies and percentages. One-
way analysis of variance (ANOVA) was used to compare the
two groups (treatment failure and success) of patients. A p
value of <0.05 was considered significant. Significant vari-
ables for treatment failure on one-way ANOVA (i.e., variables
with p values <0.05) were selected for multivariate analysis
using multiple logistic regression. A p value <0.05 was
deemed to indicate a significant difference.
3. Results
Sixty-seven consecutive patients (44 male, 23 female; mean
age ¼ 67.7 years; range ¼ 21e94 years) undergoing diag-
nostic angiography followed by TAE were included in this
study. There were 28 total procedures performed for foregut
pathology, 29 for mid-gut lesions, nine for hindgut hemor-
rhage and one transpapillar GIB. Demographic data and
bleeding parameters at the time of presentation of GIB for
patients in the success and failure groups are summarized in
Table 1. There were no significant differences in sex, age,
comorbidities, drug history, coagulation profile, platelet count,
blood transfusion during the episode, and presence of shock
between the two groups. There was a higher proportion of
patients with uremia in the failure group than in the success
group (n ¼ 9 vs. 3; p < 0.05). Patients in the failure group had
lower hemoglobin levels (6.4 vs. 7.4 mg/dL; p < 0.05) during
onset of acute bleeding and a higher proportion of coagulop-
athy (n ¼ 9 vs. 3; p < 0.05).3.1. Causes of bleeding and angiographic findingsThe causes of GIB, its duration prior to angiography,
angiographic findings and embolization variables of the two
groups are listed in Table 2. Causes of hemorrhage included
bleeding ulcer [n ¼ 50 (74.6%)], intra-abdominal malignancy
[n ¼ 5 (7.5%)], infection [n ¼ 2 (3.0%)], trauma [n ¼ 2
(3.0%)], and angiodysplasia [n ¼ 8 (11.9%)]. There were no
significant differences between the two groups in the causes
and anatomic localization of bleeding, bleeding vascular
territory, and duration of bleeding prior to angiography. In two
patients, the cause of bleeding remained obscure. Endoscopic
findings suggested hemobilia when endoscopic exploration of
the case of transpapillar bleeding was performed. The etiology
of bleeding was hemorrhagic cholecystitis confirmed by
surgical pathology. There were no significant differences in
embolic agents used, whether gelatin sponges, coils, or both.
Table 1







Male (%) 19 (54.3) 25 (78.1) 0.06
Female (%) 16 (45.7) 7 (21.9)
Age (y, mean  SD) 67.0  18.6 68.5  17.6 0.75
Comorbidity
No comorbidity (%) 12 (34.3) 13 (40.6) 0.59
Peptic ulcer disease (%) 17 (48.6) 11 (34.4) 0.24
Heart disease (%) 6 (17.1) 6 (18.8) 0.86
Liver disease (%) 6 (17.1) 6 (18.8) 0.86
Cerebrovascular disease (%) 4 (11.4) 5 (15.6) 0.62
Uremia (%) 3 (8.6) 9 (28.1) <0.05
Drug history
None (%) 6 (17.1) 7 (21.9) 0.63
NSAIDs (%) 3 (8.6) 3 (9.4) 0.91
Anticoagulants (%) 26 (74.3) 22 (68.8) 0.62
Hemoglobin (mg/dL)
Onset of acute bleeding 7.4 6.4 <0.05
72 h after transarterial
treatment
11.4 10.7 0.17
Prothrombin time (s) 13.1 14 0.15
Partial thromboplastin time (s) 34 34.6 0.88
International Normalized Ratio 1.31 1.47 0.26




2683  2614 3217  2604 0.41
Presence of shocka 17 (48.6) 19 (59.4) 0.38
Presence of coagulopathyb 3 (8.6) 9 (28.1) <0.05
30 day mortality 0 (0) 17 (53.1) N/A
Data are expressed as number of patients, and data in parentheses are
percentages.
Age and blood transfusion are represented as mean  standard deviation (SD).
N/A ¼ not applicable.
a Shock is defined as hypovolemic shock with the need of intravenous
administration of catecholamines.
b Coagulopathy is defined as International Normalized Ratio > 1.6.
Table 2







Durationa (h), mean 29.29 18.25 0.25
Embolizer
Gelatin sponge (%) 16 (45.7) 10 (31.2) 0.47
Coil (%) 10 (28.6) 11 (34.4)
Both (gelatin
sponge þ coil) (%)
9 (25.7) 11 (34.4)
Localization
Stomach (%) 5 (14.3) 4 (12.5) 0.83
Duodenum (%) 8 (22.9) 11 (34.4) 0.30
Small intestine (%) 8 (22.9) 11 (34.4) 0.30
Colon (%) 8 (22.9) 5 (15.6) 0.46
Rectum (%) 5 (14.3) 0 (0) 0.03
Bleeding vascular territory
Gastroduodenal artery (%) 10 (28.6) 11 (34.4) 0.61
Hepatic artery (%) 3 (8.6) 1 (3.1) 0.35
Left gastric artery (%) 1 (2.9) 3 (9.4) 0.13
Superior mesenteric
artery (%)
13 (40) 16 (50) 0.41
Inferior mesenteric
artery (%)
4 (11.4) 1 (3.1) 0.20
Iliac artery (%) 4 (11.4) 0 (0) 0.07
No. of supplying arteries
¼1 (%) 21 (60) 8 (25) <0.05
>1 (%) 14 (40) 24 (75)
Distanceb
5 cm (%) 24 (68.6) 11 (34.4) <0.05
>5 cm (%) 11 (31.4) 21 (65.6)
Pseudoaneurysm
Present (%) 6 (17.1) 8 (25) 0.43
Not present (%) 29 (82.9) 24 (75)
Final etiology of bleeding
Tumor bleeding (%) 3 (8.6) 2 (6.3) 0.18
Ulcer (%) 27 (77.1) 23 (71.9) 0.53
Infection (%) 0 (0) 2 (6.2) 0.13
Trauma (%) 1 (2.9) 1 (3.1) 0.95
Angiodysplasia (%) 4 (11.4) 4 (12.5) 0.90
Data are expressed as number of patients, and data in parentheses are
percentages.
a Duration is defined as time from onset to angiography, and represented as
the mean value.
b Distance is defined as the shortest intra-arterial distance between the
catheter tip to the bleeder at the time of embolization.
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artery (Fig. 1) and a distance (defined as the shortest intra-
arterial distance between the catheter tip at the time of
embolization and the bleeder) of >5 cm (Fig. 2) were both
significantly different between the two groups. There was no
significant difference between the two groups in the presence
of pseudoaneurysm.3.2. Analysis of treatment failureThe clinical and angiographic findings predicting treatment
failure are listed in Table 3. Univariate analysis showed that
a lower hemoglobin level before angiography [odds ratio
(OR) ¼ 1.32; 95% confidence interval (CI) ¼ 1.0e1.7;
p ¼ 0.036], presence of a coagulation disorder [OR ¼ 4.17;
95% CI ¼ 1.0e17.2; p ¼ 0.037], uremia [OR ¼ 4.17; 95%
CI ¼ 1.0e17.2; p ¼ 0.046], more than one supplying artery
[OR ¼ 4.50; 95% CI ¼ 1.6e12.8; p ¼ 0.004], and a distance
of >5 cm [OR ¼ 4.17; 95% CI ¼ 1.5e11.5; p ¼ 0.005] areassociated with treatment failure after TAE. In multiple
logistic regression analysis, there was a significant relationship
between treatment failure and the presence of a coagulation
disorder [OR ¼ 14.74; 95% CI ¼ 2.0e105; p ¼ 0.007], more
than one supplying artery [OR ¼ 13.19; 95% CI ¼ 2.7e64.1;
p ¼ 0.001], or a distance of >5 cm [OR ¼ 6.33; 95%
CI ¼ 1.6e24.7; p ¼ 0.008]. The presence of coagulopathy is
the most important factor associated with treatment failure.
Uremia, which was often present in patients who had coagu-
lation disorders, was not identified as a predictor of treatment
failure in the multivariate analysis because of interaction
between these two factors.
Fig. 1. Multiple supplying bleeders existed in a 73-year-old man with massive lower gastrointestinal bleeding (GIB). (A) Selective angiography shows contrast
medium extravasation in the cecum with multiple supplying vessels. Extravasation of contrast medium from the ileocolic branch of the superior mesenteric artery is
seen (arrows); and (B) control angiogram after gelatin sponge and coil embolization shows complete occlusion of the bleeding branch (arrow), with no active
bleeding. However, the patient underwent surgical intervention 3 days later because of recurrent bleeding.
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procedure. One patient, who had abdominal pain after embo-
lization of the gastroduodenal artery with coils and gelatin
sponges, was diagnosed with duodenal ischemia after endos-
copy. Endoscopic findings consisted of multiple duodenal
erosive lesions, which were interpreted as ischemic changes.
The patient had no predisposing factors for ischemia, such as
earlier abdominal surgery or radiation therapy. The symptoms
resolved with conservative therapy. A second patient, with
self-resolving abdominal pain after embolization of the
gastroduodenal artery with coils and gelatin sponges, was also
suspected of having transient duodenal ischemia based on his
symptoms. The patient developed moderate epigastric pain
and nausea hours after embolization, and the endoscopist
reported only non-specific erythema of the duodenal mucosa.
The symptoms improved the next day and resolved after 2Fig. 2. Embolization at a too-proximal location in a 68-year-old man with acute low
medium extravasated from a slender branch of the superior mesenteric artery (arrow
and (C) refilling of the distal collateral circulation occurred 1 day after embolizatdays without treatment. Visceral organ infarction complicated
recovery in one patient. Partial infarction of the right liver lobe
ensued after embolization for traumatic arteriobiliary fistula in
a patient with cirrhosis of the liver associated with portal vein
thrombosis. Conservative treatment was successful. Lastly,
a patient with an underlying coagulopathy developed an
inguinal hematoma at the puncture site after embolization,
which was treated conservatively.
Two patients developed transient renal failure during the
peri-procedural period, which could not be directly attribut-
able to the embolization procedure. There were no cases of
permanent renal insufficiency.3.4. Short-term outcome and in-hospital survivalThirty-five (52%) of 67 patients who underwent TAE had
no clinical evidence of re-bleeding and hence received no
further treatment for GIB after 7 days. Treatment failureer gastrointestinal bleeding (GIB). (A) Selective angiography showing contrast
); (B) post coil embolization, there is no evidence of active bleeding (arrows);
ion (arrow).
Table 3
Clinical and angiographic findings predicting failure: univariate and multivariate results.
Variables Failure rate Univariate analysis Multivariate analysis
(%) OR (95% CI) p OR (95% CI) p
Pre-hemoglobin N/A 1.32 (1.0e1.7) 0.036 1.40 (1.0e2.0) 0.065
Coagulopathy 75 (9/12) 4.17 (1.0e17.2) 0.037 14.74 (2.0e105) 0.007
Uremia 75 (9/12) 4.17 (1.0e17.2) 0.046 3.20 (0.6e17.1) 0.170
No. of supplying arteries >1 63 (24/38) 4.50 (1.6e12.8) 0.004 13.19 (2.7e64.1) 0.001
Distance > 5 cm 66 (21/32) 4.17 (1.5e11.5) 0.005 6.33 (1.6e24.7) 0.008
Numbers in parentheses are the number of failure cases out of the total number of cases.
N/A ¼ not applicable; OR (95% CI) ¼ odds ratio (95% confidence interval).
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active bleeding within 7 days which required surgery, and/or
who died within 1 month. Surgical interventions were per-
formed in 22 (68%) of 32 patients, with clinical evidence of
persisting or recurrent GIB, which was confirmed by the
transfusion of more units of packed cells and lower hemo-
globin concentrations after TAE. Seven of the 22 patients died
during their subsequent hospitalization (persistent GIB, n ¼ 6;
sepsis, n ¼ 1). The other 10 (32%) patients, who did not
receive surgery, died from causes related to persistent bleeding
(n ¼ 5), cardiac failure (n ¼ 2), acute respiratory distress
syndrome (n ¼ 2), or septic shock (n ¼ 1). The overall in-
hospital mortality was 25.4% (17 of 67 patients).4. Discussion
TAE is widely accepted for the termination of acute GIB
resistant to medical and endoscopic hemostasis, especially in
those considered a poor risk for surgery.7,11 This practice is
supported by the results of our study with a treatment success
rate of 52.2% (35 of 67 patients). To our knowledge, prior
authors have documented higher success rates than ours
associated with mesenteric embolization for acute GIB.9,15
However, by their definition of procedural success rate, these
studies did include patients with early rebleeding and with in-
hospital mortality related to this bleeding episode as their
procedural success group. The two conditions are defined as
treatment failure in our study, which can reflect a patient’s
clinical outcome more accurately. In our study, we also ana-
lyzedthe clinical and angiographic risk factors influencing
treatment failure, which have yet to be addressed adequately.
Despite recent developments in a variety of endoscopic
therapies, failure of endoscopic management occurs quite
frequently. About 5e10% of patients still require surgery or
angiographic intervention, either to locate or to control the
source of bleeding. Endoscopic identification of the source
artery may be limited by the considerable amount of blood
and/or feces present in the GI tract. However, the result of
surgical intervention largely depends upon the identification of
the bleeding point.5 Diagnostic angiography is necessary if
a bleeding site cannot be identified endoscopically or if
a transarterial intervention is being considered as a treatment
option.In examining the angiographic findings of patients who
received TAE, we were able to identify certain risk factors
which predicted treatment failure. We found statistical
evidence that multiple arteries supplying the bleeding site
(OR ¼ 13.19; 95% CI ¼ 2.7e64.1; p ¼ 0.001) and a distance
between the catheter tip and the bleeding point of >5 cm
(OR ¼ 6.33; 95% CI ¼ 1.6e24.7; p ¼ 0.008) are high-risk
factors for treatment failure. It was suggested that inflamma-
tory or ischemic reactions after embolization could trigger
vasodilation of the intramural collaterals, resulting in
rebleeding.9 Re-canalization through the extensive collaterals
in the duodenal blood supply in upper GIB, or collaterals
between the vasa recta in lower GIB, could be responsible for
recurrence after technical success (cessation of bleeding at the
time of embolization). With more supplying vessels, the
bleeding site could potentially have more collaterals related to
it. When a dual or multiple blood supply exists, retrograde
filling might occur through an alternate route. Moreover,
embolization at a too-proximal location (because of vessel
tortuosity or vasospasm) may allow refilling of distal collateral
circulation. Lang reported that recurrent duodenal ulcer
bleeding could be effectively eliminated with a superselective
approach to occlude the bleeding intramural artery.17 In
a series of patients with lower gastrointestinal hemorrhage,
Peck et al18 proposed a similar mechanism for rehemorrhage
after embolization with absorbable gelatin sponges and
microcoils.
Apparently, clinical factors play an important role in the
failure of TAE in acute GIB. TAE, like surgery, does not treat
the underlying disease, such as peptic ulcer disease or coa-
gulopathy. Encarnacion et al11 found an association between
coagulopathy and clinical failure after TAE in GIB
(OR ¼ 2.9). Furthermore, Defreyne et al9 reported that
rebleeding and coagulopathy after embolization were directly
correlated with in-hospital mortality. In our series, this asso-
ciation was confirmed with the finding of an even stronger
significance (OR ¼ 14.74). This highlights the importance of
correcting any coagulation disorder in patients with GI
hemorrhage before, during, and after intervention.
Although in this study hemoglobin concentration was not
identified as a predictor of re-bleeding in the multivariate
analysis because of its interaction with coagulopathy
( p ¼ 0.065), recurrence of bleeding was associated with
a lower hemoglobin level (mean ¼ 6.4 mg/dL vs. 7.4 mg/dL;
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severe and abrupt nature of the GIB in the failure group. Signs
of active bleeding and shock at admission are proposed risk
factors for rehemorrhage after endoscopic hemostasis, and
could be an additional risk factor for early recurrence after
embolization.9,19 However, we found no correlation between
the presence of shock and rebleeding.
Arterial embolization in the upper GI tract is generally
considered very safe because of the rich collateral supply to
the stomach and duodenum. The risk of significant ischemia
after embolization is known to increase in patients with
previous surgery within the same area, or with embolic
agents that can advance far into the vascular bed such as
tissue adhesives or gelatin sponge powder.17,20 Lang17
reported duodenal stenosis as a sequela of ischemia in
seven of 28 patients with embolization of terminal vessels,
mostly when tissue adhesive was used, and in only two of 29
patients with more proximal occlusion of the gastroduodenal
artery. In lower GIB, several authors have confirmed that
polyvinyl alcohol particles (PVAs) and platinum microcoils
are safe and curative. PVAs injected just proximally to the
vas rectum, seem to flow along the path of least resistance,
particularly the ruptured vas rectum, and to reduce the risk
of bowel ischemia. Nicholson et al16 reported that proximal
occlusion was considered responsible for ischemic colonic
strictures in three (21%) of 14 patients, all of whom were
treated conservatively.
The absence of major bowel ischemic events in our series
indicated that we delivered the embolic material in the right
amount and at the right place; we used platinum microcoils
and gelatin sponge plugs rather than PVAs or glue. Embolic
material was delivered only when a superselective approach
into the bleeding vessel could be achieved, while carefully
avoiding filling normal branches. Thus, we narrowed the risk
area by performing superselective embolization into the
ruptured mural artery.
Our study has several limitations. Firstly, patients without
angiographic evidence of GIB (intraluminal contrast
leakage) were not included, because the exact localization
for TAE could not be determined. In addition, we also did
not include patients with acute GIB who directly underwent
surgical intervention. The optimal time to perform angiog-
raphy or surgery is sometimes a difficult clinical decision,
because of the intermittent nature of GIB. Secondly, this
study was retrospective. Although criteria were applied for
TAE, the use of coils and the number of gelatin sponge
pieces used were not standardized. The experience of the
three radiologists differed. In spite of these, the study does
represent a large single-center experience with a variety of
GI pathologies from various locations. Further clarification
of the role of angiographic risk factors in predicting long-
term survival requires prospective, randomized, control
studies.
In conclusion, in patients with endoscopically unmanage-
able acute GIB, TAE is advised as the first approach to
treatment, because it offers effective and safe nonsurgical
healing in a large number of cases. In addition, patients withcertain risk factors, such as a distance of >5 cm, more than
one supplying artery or the presence of coagulopathy, are at
higher risk for treatment failure and should be watched care-
fully for recurrence in the post-procedural period. Even with
possible treatment failure, diagnostic angiography can
still provide additional informationto facilitate a better
therapeuticplan.Acknowledgments
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